Information Provided By:
Fly News Breaks for July 11, 2018
BSX, NVRO
Jul 11, 2018 | 14:39 EDT
JPMorgan analyst Robert Marcus said that after his talks with Nevro's (NVRO) management team he is more positive on the company's positioning in its ongoing legal fight against Boston Scientific (BSX). Headlines regarding a tentative ruling that supported invalidating 5 of the 7 patents at issue, which he attributes for Nevro's decline yesterday, masked that the judge favored Nevro on the two remaining patents and the company only needs to successfully defend one of its patents to keep Boston Scientific out of the market, Marcus tells investors. He maintains an Overweight rating on Nevro shares.
News For NVRO;BSX From the Last 2 Days
BSX
Mar 26, 2024 | 05:33 EDT
Scivita Medical and Boston Scientific joined hands again to sign an expanded strategic cooperation arrangement. The introduction of iterative endoscopic technology has brought about a positive transformation in the field of endoscopy, making it an interventional tool that combines diagnosis and treatment. Under the arrangement, Scivita Medical will expand its relationship with Boston Scientific for strategic co-development and global distribution activities. Such activities may include collaboration on the co-development of future endoscopic devices, and global distribution opportunities for Scivita Medical's single-use endoscope and imaging devices. It is expected that this expanded arrangement will help bring Scivita Medical products to more hospitals and patients throughout China and other global geographies.